Table 2 Correlation of GABPA mRNA expression with clinic-pathological features in hepatocellular carcinoma
From: GABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma
Variables | Category | GABPA (N > C) | Number of case | P Value |
|---|---|---|---|---|
Age | <50 | 20 (76.9%) | 26 | 0.356 |
≥50 | 30 (66.7%) | 45 | ||
Gender | Male | 41 (70.7%) | 58 | 0.917 |
Female | 9 (69.2%) | 13 | ||
Tumor size | <5 cm | 18 (69.2%) | 26 | 0.867 |
≥5 cm | 32 (71.1%) | 45 | ||
AFP(ng/ml) | <400 | 11 (45.8%) | 24 | 0.001* |
≥400 | 39 (83.0%) | 47 | ||
HBsAg | Negative | 12 (70.6%) | 17 | 0.986 |
Positive | 38 (70.4%) | 54 | ||
Cirrhosis | Absent | 22 (73.3%) | 30 | 0.646 |
Present | 28 (68.3%) | 41 | ||
Tumor grade | Low | 45 (76.3%) | 59 | 0.017* |
High | 5 (41.7%) | 12 | ||
Metastasis | Yes | 36 (80.0%) | 45 | 0.021* |
No | 14 (53.8%) | 26 |